RxDoctor Payments Data

Jose Garcia Mateo, MD

Endocrinology, Diabetes & Metabolism · Ponce, PRNPI 1932275484

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $771,846 of the $944,576 with a category attached, or 81.7%. 34 manufacturers reported payments, led by Lilly USA, LLC at 27.2% of the total. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$944,576in general payments, 2019–2025

Across 1,620 payments — averaging $583.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$257K
  • AstraZeneca$164K
  • Boehringer Ingelheim$114K
  • Bayer$101K
  • Amgen$93K
  • Sanofi-aventis U.S. LLC$66K
  • plus $150K from 28 others

What the payments were for

  • Consulting fees$31,1073%
  • Speaking & faculty fees$771,84682%
  • Travel & lodging$94,60710%
  • Food & beverage$46,9255%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$944,576 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,047
Medicare patients
70
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide1,160$1,160,626
KorlymMifepristone12$587,586
FarxigaDapagliflozin Propanediol869$567,714
OzempicSemaglutide557$552,006
JardianceEmpagliflozin672$469,769
MounjaroTirzepatide345$371,773
Synjardy XrEmpagliflozin/Metformin Hcl378$249,542
Soliqua 100-33Insulin Glargine/Lixisenatide262$235,638
KerendiaFinerenone314$232,267
Repatha SureclickEvolocumab297$169,059
ForteoTeriparatide33$144,772
SynthroidLevothyroxine Sodium2,374$144,671
JanumetSitagliptin Phos/Metformin Hcl150$103,783
JanuviaSitagliptin Phosphate142$100,672
TymlosAbaloparatide36$96,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog$256,840$1,697,9471,674 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Glyxambi$113,873$986,2491,467 claims
AstraZenecaFarxiga, Brilinta, Lokelma$164,350$620,984959 claims
Corcept TherapeuticsKorlym$27,461$587,58612 claims
Novo NordiskOzempic$477$552,006557 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$66,005$307,097955 claims
MerckJanumet, Januvia, Janumet Xr$418$252,443367 claims
BayerKerendia$101,350$232,267314 claims
AbbVieSynthroid$2,993$144,6712,374 claims
AmgenProlia, Evenity (2 Syringes)$92,608$136,88268 claims
Radius Health, Inc.Tymlos$230$96,31336 claims
Johnson & JohnsonXarelto, Invokana$49,927$81,017115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →